Last day of trading with unit rights in Peptonic’s rights issue

Peptonic Medical is conducting a rights issue as part of its restructuring plan: trading in unit rights ends 23 January 2026, subscription runs 14–28 January 2026 with record date 9 January 2026. One unit equals 100 new shares plus 100 warrants (TO6); 100 unit rights subscribe one unit. If fully subscribed the company will raise approximately SEK 14.9m before costs and could receive an additional ~SEK 14.9m upon full warrant exercise, while any unsold/unused unit rights will expire worthless — a dilutionary capital raise that addresses near-term liquidity but signals restructuring-related funding needs.

Analysis

Market structure: The rights issue creates immediate capital but also a blunt dilution: full subscription issues ~SEK 14.9m now and, if warrants (TO6) are exercised, another SEK 14.9m — implying roughly +100% potential share count (≈50% immediate dilution and a further ~50% if warrants convert). Winners are short-term rights traders and holders who can buy and exercise cheaply; losers are legacy shareholders facing abrupt EPS/sharebook erosion and any creditors that priced on pre-money metrics.

Risk assessment: Tail risks include a failed take-up (<50%) triggering near-term liquidity distress or forced asset sales, and regulatory/market fragmentation because Peptonic cannot freely tap US investors (adds execution risk for its US push). Immediate timeline: rights trading ends 23 Jan, subscription closes 28 Jan (days); watch cash runway and subscription ratio over next 7–30 days; material operational effects (US expansion, revenue inflection) are 12–24 months out.

Trade implications: If you can borrow the stock, consider a tactical short (size 0.5–2% NAV) with stop-loss at +30% and target 40–70% downside if dilution is priced in; hedge with a long position in large-cap consumer healthcare (PG, 1–2% NAV) as defensive pair. If unit-rights trade >10% below theoretical ex-rights value, buy rights and exercise (allocate up to 0.5% NAV) — breakeven comes from eventual warrant optionality and retained shares; if rights take-up <70% increase short exposure within 48–72 hours of subscription close.

Contrarian angles: Market may over-discount the brands (VagiVital, Vernivia); if management delivers full subscription + warrant exercise, cash runway could double and enable a credible US commercial push or bolt-on deals, producing a >2x upside over 12–24 months. Historical parallel: small medtech rights that clear financing and execute U.S. launches have re-rated; monitor subscription % and early US channel wins as binary catalysts that would reverse a short thesis.

Key Decisions for Investors

• Establish a tactical short position in Peptonic Medical equal to 0.5–2.0% of fund NAV (or maximum borrow available) within 3 trading days; set hard stop-loss at +30% and tranche out to realize profits at 40–70% downside, increasing size if subscription uptake <70% after 28 Jan.
• Initiate 1–2% NAV long in defensive consumer-health leaders (Procter & Gamble: PG, Haleon: HLN.L) as a pair trade hedge against medtech small-cap idiosyncratic risk; use this to capture sector flow into stable OTC revenues while shorting Peptonic.
• If unit-rights quote >10% below theoretical ex-rights value before 23 Jan, buy rights and subscribe (size up to 0.5% NAV) to capture arbitrage and free warrants; only execute if estimated all-in cost implies >20% discount to implied pro forma market cap.
• Reassess positions within 7 trading days after subscription close (28 Jan): if take-up ≥95% and warrants formally priced to exercise, reduce short exposure by 50% within 30 days; if take-up ≤70%, add to short and avoid any long exposure until 3Q–4Q 2026 evidence of US traction.